Silva B, Miglietta E, Casabona J, Wenker S, Eizaguirre M, Alonso R
Front Immunol. 2024; 15:1431403.
PMID: 39224589
PMC: 11366620.
DOI: 10.3389/fimmu.2024.1431403.
Morollon N, Belvis R, De Dios A, Pages N, Gonzalez-Oria C, Latorre G
Neurologia. 2024; 35(9):628-632.
PMID: 38620330
PMC: 7386293.
DOI: 10.1016/j.nrl.2020.07.007.
Garcia-Dominguez M, Kipkorir V, Srichawla B
Ann Med Surg (Lond). 2024; 86(2):720-725.
PMID: 38333271
PMC: 10849302.
DOI: 10.1097/MS9.0000000000001676.
Eskandarieh S, Sahraian M, Naser Moghadasi A
Curr J Neurol. 2023; 20(4):241-245.
PMID: 38011483
PMC: 9107576.
DOI: 10.18502/cjn.v20i4.8351.
Bazylewicz M, Gudowska-Sawczuk M, Mroczko B, Kochanowicz J, Kulakowska A
Int J Mol Sci. 2023; 24(11).
PMID: 37298185
PMC: 10253145.
DOI: 10.3390/ijms24119231.
Strategies for the Emergency Treatment of Pregnant Women with Neurological Symptoms during the COVID-19 Pandemic.
Yang H, Fan Y, Zhu Z, Wu H, Chen Z, Hu X
Aging Dis. 2023; 14(2):290-298.
PMID: 37008058
PMC: 10017149.
DOI: 10.14336/AD.2022.0718.
Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases.
Greco R, Snowden J, Knelange N, Tridello G, Cacciatore C, Xhaard A
J Autoimmun. 2023; 136:103024.
PMID: 37001437
PMC: 9977622.
DOI: 10.1016/j.jaut.2023.103024.
The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs.
Askari H, Rabiei F, Lohrasbi F, Ghadir S, Ghasemi-Kasman M
Brain Sci. 2023; 13(3).
PMID: 36979225
PMC: 10046222.
DOI: 10.3390/brainsci13030415.
Multiple sclerosis and COVID-19: A retrospective study in Iran.
Sedighi B, Haghdoost A, Jangipour Afshar P, Abna Z, Bahmani S, Jafari S
PLoS One. 2023; 18(3):e0283538.
PMID: 36952532
PMC: 10035930.
DOI: 10.1371/journal.pone.0283538.
Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R, Amin R, Riddick L, Roy S, Wolff S, Nathanson A
Mult Scler Relat Disord. 2023; 71:104575.
PMID: 36857853
PMC: 9924032.
DOI: 10.1016/j.msard.2023.104575.
A review article on neuroprotective, immunomodulatory, and anti-inflammatory role of vitamin-D3 in elderly COVID-19 patients.
Tripathi A, Mishra S
Egypt J Neurol Psychiatr Neurosurg. 2023; 59(1):18.
PMID: 36776226
PMC: 9901404.
DOI: 10.1186/s41983-023-00611-z.
Risk and prognostic factors for SARS-CoV-2 infection in Spanish population with multiple sclerosis during the first five waves.
Pilo de la Fuente B, Martin-Moro J, Martin Avila G, Mendez Burgos A, Ramos Barrau L, Thuissard I
Front Neurol. 2022; 13:1001429.
PMID: 36341098
PMC: 9626970.
DOI: 10.3389/fneur.2022.1001429.
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.
Bilge N, Can F, Yevgi R
Acta Neurol Belg. 2022; 123(5):1885-1892.
PMID: 36331727
PMC: 9638386.
DOI: 10.1007/s13760-022-02125-6.
COVID-19 Outcomes in Hospitalized Patients With Neurodegenerative Disease: A Retrospective Cohort Study.
Patel R, Stebbins G, Kishen E, Barton B
Neurol Clin Pract. 2022; 12(1):43-51.
PMID: 36157630
PMC: 9491511.
DOI: 10.1212/CPJ.0000000000001117.
Implementing education: Personal communication with a healthcare professional is a critical step to address vaccine hesitancy for people with multiple sclerosis.
Panisset M, Kilpatrick T, Cofre Lizama L, Galea M
Mult Scler Relat Disord. 2022; 63:103933.
PMID: 35671672
PMC: 9158244.
DOI: 10.1016/j.msard.2022.103933.
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Sancho-Saldana A, Gil Sanchez A, Quirant-Sanchez B, Nogueras L, Peralta S, Solana M
J Clin Med. 2022; 11(9).
PMID: 35566632
PMC: 9099725.
DOI: 10.3390/jcm11092509.
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?.
Baker D, MacDougall A, Kang A, Schmierer K, Giovannoni G, Dobson R
Clin Exp Immunol. 2022; 207(3):263-271.
PMID: 35553629
PMC: 9113152.
DOI: 10.1093/cei/uxab015.
Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance.
Zaratin P, Banwell B, Coetzee T, Comi G, Feinstein A, Hyde R
Mult Scler J Exp Transl Clin. 2022; 8(2):20552173221099181.
PMID: 35530174
PMC: 9073122.
DOI: 10.1177/20552173221099181.
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
Alroughani R, Inshasi J, Al-Hashel J, Alkhaboury J, AlSalti A, Al Suwaidi R
J Clin Neurosci. 2022; 99:311-316.
PMID: 35339046
PMC: 8866083.
DOI: 10.1016/j.jocn.2022.02.033.
Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments.
Money K, Baber U, Saart E, Samaan S, Sloane J
Front Neurol. 2022; 13:843081.
PMID: 35280260
PMC: 8905651.
DOI: 10.3389/fneur.2022.843081.
